There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...

University of Cambridge study shows how LLM GPT-4 can generate novel combinations of drugs not typically used to treat cancer ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...